Moderna stock outlook rises after profit returns in Q3
Published on 11/12/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat changes for Moderna investors
- Third-quarter revenue reached 1.3 billion US dollars, while GAAP net income was 0.2 billion US dollars.
- Management raised expected 2026 revenue growth to 15% to 25%, from a previous expectation of up to 10%.
- Positive Phase 3 data for intismeran and US approval for mFLUSIVA broaden the companys near-term pipeline and product base.
Moderna stock traded at 220.53 euros on Lang & Schwarz at 14:00 CET on Thursday, November 12, 2026.
Moderna reported a return to profitability for the third quarter and lifted its 2026 revenue outlook, according to the companys investor-relations release published on November 6. The update gives investors a stronger near-term operating picture, but the companys vaccine demand and development pipeline remain central to the longer-term assessment.
Profit return supports higher outlook
Moderna reported third-quarter revenue of 1.3 billion US dollars, GAAP net income of 0.2 billion US dollars and diluted earnings per share of 0.38 US dollars. The figures marked a return to profit after the company had faced a loss in the comparable period, while revenue growth and tighter cost control improved the quarterly backdrop.
Management now expects total revenue to grow 15% to 25% in 2026. The new range exceeds the previous expectation of up to 10% growth. Moderna also raised its expected year-end cash and investments to 8.1 billion to 8.3 billion US dollars and improved its 2026 GAAP operating-expense outlook by approximately 0.2 billion US dollars.
Pipeline milestones add another test
The company highlighted positive Phase 3 data for intismeran and the US Food and Drug Administration approval of mFLUSIVA, which Moderna described as its fifth approved product globally. Those milestones add commercial and development support beyond the established Covid vaccine franchise, although their contribution to revenue will depend on regulatory progress, launches and demand.
For investors, the raised outlook reduces some of the immediate pressure on the recovery plan. The quality of the improvement still depends on vaccine sales across international markets, the pace of cost reductions and the companys ability to turn pipeline assets into durable products. The higher cash outlook provides additional financial flexibility, while financing and development spending remain relevant to future dilution and profitability.
The S&P 500 sets the broader US equity-market backdrop for Moderna investors.
Further reports and analysis are available on the Moderna stock.
Moderna Inc. key figures
- Company: Moderna Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Home exchange: Nasdaq
- Lang & Schwarz price: 220.53 euros at 14:00 CET on November 12, 2026
- Third-quarter revenue: 1.3 billion US dollars
- Third-quarter GAAP net income: 0.2 billion US dollars
- 2026 revenue outlook: 15% to 25% growth
